Journal article icon

Journal article

Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.

Abstract:

Conventional surgery and radiotherapy for acromegaly have limitations. There are few data on the use of the somatostatin analog octreotide (Oct) as primary medical therapy. An open prospective study of 27 patients with newly diagnosed acromegaly was conducted in nine endocrine centers in the United Kingdom. Twenty patients had macroadenomas, and 7 had microadenomas. For the first 24 wk (phase 1), patients received sc Oct in an initial dose of 100 microg, 3 times daily, increased to 200 micro ...

Expand abstract

Actions


Access Document


Publisher copy:
10.1210/jc.2001-012012

Authors


Atkinson, AB More by this author
Bouloux, PM More by this author
Expand authors...
Journal:
The Journal of clinical endocrinology and metabolism
Volume:
87
Issue:
10
Pages:
4554-4563
Publication date:
2002-10-05
DOI:
EISSN:
1945-7197
ISSN:
0021-972X
URN:
uuid:e7c098b7-99da-4e60-a615-4a0968214544
Source identifiers:
95859
Local pid:
pubs:95859

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP